Buy Ziprasidone (Geodon) online

Buy Geodon (Ziprasidone Hydrochloride) atypical antipsychotic
Cheap qualitative Ziprasidone 20 mg, 40 mg, 80 mg capsules online



HOW AND WHERE TO BUY ZIPRASIDONE (GEODON) 20 MG, 40 MG, 80 MG CAPSULES OR TABLETS ONLINE:

GEODON: PRESCRIBING INFORMATION

DESCRIPTION

Geodon is available as capsules (Ziprasidone Hydrochloride) for oral administration and as an injection (Ziprasidone Mesylate) for intramuscular use only. Ziprasidone is a psychotropic agent that is chemically unrelated to phenothiazine or butyrophenone antipsychotic agents. It has a molecular weight of 412.94 (free base), with the following chemical name: 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one. The empirical formula is C21H21ClN4OS (free base of ziprasidone).

Geodon capsules contain a monohydrochloride, monohydrate salt of ziprasidone. Chemically, ziprasidone hydrochloride monohydrate is 5-[2-[4-(1,2benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one, monohydrochloride, monohydrate. The empirical formula is C21H21ClN4OSxHClxH2O and its molecular weight is 467.42. Ziprasidone Hydrochloride Monohydrate is a white to slightly pink powder.

Geodon capsules are supplied for oral administration in 20 mg (blue / white), 40 mg (blue / blue), 60 mg (white / white), and 80 mg (blue / white) capsules. Geodon capsules contain Ziprasidone Hydrochloride Monohydrate, lactose, pregelatinized starch, and magnesium stearate.

Geodon for injection contains a lyophilized form of Ziprasidone Mesylate Trihydrate. Chemically, ziprasidone mesylate trihydrate is 5-[2-[4-(1,2-benzisothiazol-3yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-2-one, methanesulfonate, trihydrate. The empirical formula is C21H21ClN4OSxCH3SO3Hx3H2O and its molecular weight is 563.09.

Geodon for injection is available in a single-dose vial as ziprasidone mesylate (20 mg ziprasidone / ml when reconstituted according to label instructions). Each mL of Ziprasidone Mesylate for injection (when reconstituted) contains 20 mg of ziprasidone and 4.7 mg of methanesulfonic acid solubilized by 294 mg of sulfobutylether beta-cyclodextrin sodium (SBECD).


INDICATIONS AND USAGE

Geodon indications and usage


DOSAGE AND ADMINISTRATION

Geodon dosage and administration


DOSAGE FORMS AND STRENGTHS

Ziprasidone Hydrochloride (Geodon) capsules are differentiated by capsule color/size and are imprinted in black ink with "Pfizer" and a unique number. Ziprasidone HCl (Geodon) capsules are supplied for oral administration in 20 mg (blue/white), 40 mg (blue/blue), 60 mg (white/white), and 80 mg (blue/white) capsules. They are supplied in the following strengths and package configurations: Geodon capsules strength: 20 mg, 40 mg, 60 mg, 80 mg

Geodon for injection is available in a single-dose vial as ziprasidone mesylate (20 mg ziprasidone/mL when reconstituted according to label instructions). Each mL of ziprasidone mesylate for injection (when reconstituted) affords a colorless to pale pink solution that contains 20 mg of ziprasidone and 4.7 mg of methanesulfonic acid solubilized by 294 mg of sulfobutylether beta-cyclodextrin sodium (SBECD).


CONTRAINDICATIONS

QT Prolongation

Because of ziprasidone's dose-related prolongation of the QT interval and the known association of fatal arrhythmias with QT prolongation by some other drugs, ziprasidone is contraindicated:

  • in patients with a known history of QT prolongation (including congenital long QT syndrome)
  • in patients with recent acute myocardial infarction
  • in patients with uncompensated heart failure

    Pharmacokinetic / pharmacodynamic studies between ziprasidone and other drugs that prolong the QT interval have not been performed. An additive effect of ziprasidone and other drugs that prolong the QT interval cannot be excluded. Therefore, ziprasidone should not be given with:

  • dofetilide, quinidine, sotalol, other Class Ia and III anti-arrhythmics, mesoridazine, chlorpromazine, thioridazine, droperidol, sparfloxacin, pimozide, gatifloxacin, moxifloxacin, mefloquine, halofantrine, pentamidine, levomethadyl acetate, arsenic trioxide, dolasetron mesylate, probucol or tacrolimus.
  • other drugs that have demonstrated QT prolongation as one of their pharmacodynamic effects and have this effect described in the full prescribing information as a contraindication or a boxed or bolded warning.

    Hypersensitivity

    Ziprasidone is contraindicated in individuals with a known hypersensitivity to the product.


    WARNINGS AND PRECAUTIONS

    Geodon warnings and precautions


    ADVERSE REACTIONS

    Geodon adverse reactions


    DRUG INTERACTIONS

    Geodon drug interactions


    USE IN SPECIFIC POPULATIONS

    Geodon use in specific populations


    DRUG ABUSE AND DEPENDENCE

    Dependence

    Ziprasidone (Geodon) has not been systematically studied, in animals or humans, for its potential for abuse, tolerance, or physical dependence. While the clinical trials did not reveal any tendency for drug-seeking behavior, these observations were not systematic and it is not possible to predict on the basis of this limited experience the extent to which ziprasidone will be misused, diverted, and/or abused once marketed. Consequently, patients should be evaluated carefully for a history of drug abuse, and such patients should be observed closely for signs of ziprasidone misuse or abuse (e.g., development of tolerance, increases in dose, drug-seeking behavior).


    OVERDOSAGE

    Geodon overdosage


    CLINICAL PHARMACOLOGY

    Geodon clinical pharmacology


    NONCLINICAL TOXICOLOGY

    Geodon nonclinical toxicology


    CLINICAL STUDIES

    Geodon clinical studies


    HOW SUPPLIED / STORAGE AND HANDLING

    Geodon (Ziprasidone Hydrochloride) capsules are differentiated by capsule color / size and are imprinted in black ink with "Pfizer" and a unique number. Geodon capsules are supplied for oral administration in 20 mg (blue / white), 40 mg (blue / blue), 60 mg (white / white), and 80 mg (blue / white) capsules. They are supplied in the following strengths and package configurations: Geodon capsules 20 mg, 40 mg, 60 mg, 80 mg: bottles of 60; unit dose / 80

    Ziprasidone HCl (Geodon) capsules should be stored at 25°C (77°F); excursions permitted to 15-30°C (59-86°F).

    Geodon for injection is available in a single-dose vial as ziprasidone mesylate (20 mg ziprasidone / mL when reconstituted according to label instructions). Each ml of ziprasidone mesylate for injection (when reconstituted) affords a colorless to pale pink solution that contains 20 mg of ziprasidone and 4.7 mg of methanesulfonic acid solubilized by 294 mg of sulfobutylether beta-cyclodextrin sodium (SBECD).

    Ziprasidone Mesylate (Geodon) for injection package: single-use vials, concentration 20 mg / ml

    Geodon (Ziprasidone Mesylate) for injection should be stored at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) in dry form. Protect from light. Following reconstitution, Geodon for injection can be stored, when protected from light, for up to 24 hours at 15°-30°C (59°-86°F) or up to 7 days refrigerated, 2°-8°C (36°-46°F).


    PATIENT COUNSELING INFORMATION

    See FDA-Approved Patient Labeling.

    Please refer to the patient package insert. To assure safe and effective use of Geodon (Ziprasidone), the information and instructions provided in the patient information should be discussed with patients.

    Administration with Food

    Patients should be instructed to take Geodon (Ziprasidone HCl) capsules with food for optimal absorption. The absorption of ziprasidone is increased up to two-fold in the presence of food.

    QTc Prolongation

    Patients should be advised to inform their health care providers of the following: History of QT prolongation; recent acute myocardial infarction; uncompensated heart failure; prescription of other drugs that have demonstrated QT prolongation; risk for significant electrolyte abnormalities; and history of cardiac arrhythmia.

    Patients should be instructed to report the onset of any conditions that put them at risk for significant electrolyte disturbances, hypokalemia in particular, including but not limited to the initiation of diuretic therapy or prolonged diarrhea. In addition, patients should be instructed to report symptoms such as dizziness, palpitations, or syncope to the prescriber.

    Recent posts:

  • Buy Ziprasidone (Geodon) Online

    Copyright © Buy Ziprasidone Online